Disclosed is an antibiotic aqueous dispersion composition including as an active ingredient zinc pyrithione and, at least one subsidiary antiseptic selected from the group consisting of thiamine dilauryl sulphate (TDS), a salt and glyceryl monoalkyl ether. The composition has excellent stability and wide antibiotic or antiseptic spectra to bacteria and fungus.

A method of treating a leukemia comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a compound of Formula (I) and/or (II) having the structure: OR2 R R1O n OR2 R R1O n I II wherein: 10 ---- represents a single or a double bond; R is OH when C----R is C—R, and R is O when C----R is C═R; n is 1, 3, 5 or 7; and R1 and R2 are independently hydrogen or acetyl, and/or isomers, stereoisomers or solvates thereof and/or mixtures thereof.

##STR00001##

A method of treating a leukemia comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a compound of Formula (I) and/or (II) having the structure: OR2 R R1O n OR2 R R1O n I II wherein: 10 ---- represents a single or a double bond; R is OH when C----R is C—R, and R is O when C----R is C═R; n is 1, 3, 5 or 7; and R1 and R2 are independently hydrogen or acetyl, and/or isomers, stereoisomers or solvates thereof and/or mixtures thereof.

##STR00001##

The present invention concerns a solid formulation for oral administration as a solid comprising polyethylene glycol and a further solid such as mannitol. The formulation may be used to prevent gastrointestinal disorders such as constipation in healthy subjects. In some embodiments, the solid formulation is chewable or suckable.

An ophthalmic composition of water soluble ingredients provides additional moisture to the eye by promoting moisture absorption from the air and providing long lasting relief. The composition can include two groups of ingredients, one a liquid and the other a solid. Together, the ingredients form a substance that ranges from a liquid to a gel. Benefits of such composition include longer lasting symptom relief with less applications and increased moisture production.

An ophthalmic composition of water soluble ingredients provides additional moisture to the eye by promoting moisture absorption from the air and providing long lasting relief. The composition can include two groups of ingredients, one a liquid and the other a solid. Together, the ingredients form a substance that ranges from a liquid to a gel. Benefits of such composition include longer lasting symptom relief with less applications and increased moisture production.

A modified release benzonatate solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.

A eutectic anesthetic composition used to deliver pharmaceutical products topically as well as a method for producing the eutectic anesthetic composition, which may contain up to 80% additive ingredients. Preferred embodiments of the invention may include eutectic emulsion compositions which provide high viscosity/no separation due to API, are not temperature-sensitive, have no shear stress from the ointment mill/EMP, have no gumming up/stickiness or hardening, have improved active penetration and skin adhesion, and can use larger amounts of lipophilic active substances without lessening storage stability.

A eutectic anesthetic composition used to deliver pharmaceutical products topically as well as a method for producing the eutectic anesthetic composition, which may contain up to 80% additive ingredients. Preferred embodiments of the invention may include eutectic emulsion compositions which provide high viscosity/no separation due to API, are not temperature-sensitive, have no shear stress from the ointment mill/EMP, have no gumming up/stickiness or hardening, have improved active penetration and skin adhesion, and can use larger amounts of lipophilic active substances without lessening storage stability.

Methods of inducing anesthesia in a subject by administering an effective amount of a compound or a mixture of compounds according to Formula I are provided. Compounds of Formula I are a class of halogenated alcohol derivatives with a vapor pressure of at least 0.1 atmospheres (76 mmHg) at 25° C. Compounds of Formula I can be administered by any route sufficient to achieve a desired anesthetic endpoint.